MedPath

Comparative Effectiveness of Different Surgical Approaches for Giant Pituitary Adenomas

Not Applicable
Completed
Conditions
Surgery
Pituitary Adenoma
Interventions
Procedure: Two different approaches
Registration Number
NCT05448690
Lead Sponsor
Huashan Hospital
Brief Summary

The surgical treatment strategy for giant invasive pituitary adenoma is one of the current hot spots in the field of clinical research on pituitary adenoma. A comprehensive literature search resulted in numerous previous studies to investigate the efficacy, advantages and disadvantages of different surgical options.

A single approach (transnasal or craniotomy) is theoretically less invasive and has a shorter hospital stay for the patient, but may result in postoperative bleeding due to residual tumor and damage to the intracranial vessels adhering to the tumor.

The advantage of the combined approach is that the tumor can be removed to the greatest extent possible. In addition, postoperative suprasellar hemorrhage can be prevented by careful hemostasis or intracranial drainage by the transcranial team if necessary. In this way, the risk of postoperative bleeding due to residual tumor can be significantly reduced.

In some cases, waiting a few months after the initial surgery for a second-stage procedure may also be an option when the patient's condition does not allow for a combined access procedure, when the tumor is hard, or when the blood preparation is insufficient. However, staged surgery increases the financial burden on the patient, and local scar formation may make second-stage surgery more difficult and decrease the likelihood of endocrine remission of functional pituitary tumors.

Given the complexity of the treatment of giant invasive pituitary adenoma, there is a need to conduct studies comparing the combined transnasal cranial approach, the single access transnasal or cranial approach, and the staged approach simultaneously to assess whether the combined transnasal cranial approach is superior to the single access transnasal or cranial approach or the staged approach in improving the tumor resection rate in giant invasive pituitary adenoma.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
600
Inclusion Criteria
  • Giant pituitary adenoma (> 4cm in diameter)
Exclusion Criteria
  • most of the tumor were in the sellae, sphenoidal sinus or clivus.
  • patients with craniopharyngioma or meningioma.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Combined approachTwo different approachesPatients underwent a combined approach using transnasal approach and craniotomy approach simultaneously
Primary Outcome Measures
NameTimeMethod
Extend of resectionOne month after surgery

how much tumor was resected

Secondary Outcome Measures
NameTimeMethod
Relapse or MortalityFrom date of surgery until the date of first documented date of death from any cause, assessed up to 3 months after surgery

Death from any cause

Karnofsky performance scoreThree months after surgery

Ranged from 0 to 100, the higher scores mean a better outcome

RisksOne month after surgery

Proportion of Participants with hemorrage, infection or cranial nerve defect

Trial Locations

Locations (13)

Shanghai General Hospital

🇨🇳

Shanghai, Shanghai, China

Chongqing People's Hospital

🇨🇳

Chongqing, Chongqing, China

The first affliated hospital of Fujian Medical Hospital

🇨🇳

Fuzhou, Fujian, China

The First Affiliated Hospital of Guizhou Medical University

🇨🇳

Guiyang, Guizhou, China

The First Affiliated Hospital of China Medical University

🇨🇳

Shenyang, Jilin, China

General hospital of Eastern Theater Command

🇨🇳

Nanjing, Jiangsu, China

The First Affiliated Hospital of Shandong First Medical University

🇨🇳

Jinan, Shandong, China

General Hospital of Ningxia Medical University

🇨🇳

Yinchuan, Ningxia, China

Huashan Hospital

🇨🇳

Shanghai, Shanghai, China

Shanghai Renji Hospital

🇨🇳

Shanghai, Shanghai, China

Changzhi People's Hospital

🇨🇳

Changzhi, Shanxi, China

The first hospital of Shanxi Medical University

🇨🇳

Taiyuan, Shanxi, China

The first affliated hospital of Kunming Medical University

🇨🇳

Kunming, Yunnan, China

© Copyright 2025. All Rights Reserved by MedPath